Aignostics vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aignostics is a Berlin-based computational pathology company applying AI to histopathology image analysis for drug development and clinical diagnostics; raised €45M+ total including a €37M Series B in 2024;
About
Aignostics is a Berlin-based precision pathology company founded in 2019 as a spinout from Charité – Universitätsmedizin Berlin, one of Europe''s largest university hospitals. The company develops foundation models and AI-powered image analysis tools for computational pathology — applying deep learning to digitized histopathology slides (whole slide images) to detect, classify, and quantify cellular and tissue features at scale. Its technology enables pharmaceutical companies, contract research organizations (CROs), and diagnostic laboratories to analyze tissue samples faster, more consistently, and with greater quantitative depth than human pathologists alone.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Aignostics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.